News

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease

Vivet Therapeutics’ lead program, VTX-801 for Wilson Disease, was highlighted during Pfizer’s Investor Day September 15th 2020.

PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration

Vivet is very happy to share the March 2020

Vivet Announces Publication in Nature Communications of Preclinical Data from VTX-803

Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics

PARIS, France June 12th, 2018, Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare

PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017’s

PARIS, France September 26th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product

In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However, as many as 30 million people may suffer from one of the more than 6,000 existing rare diseases.

This section of the website provides information for companies and individuals involved in developing and marketing medicines for human use in the European Union (EU)

A useful resource of Cellular & Gene Therapy Guidance Documents

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases